Chemical: Drug
pravastatin

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


Annotated Labels

  1. FDA Label for pravastatin and LDLR
  2. FDA Label for pravastatin and APOE

last updated 09/01/2016

1. FDA Label for pravastatin and LDLR

Actionable PGx
Full label available at DailyMed

Genes and/or phenotypes found in this label

  • familial hypercholesterolemia
    • Indications & usage section, Contraindications section, Adverse reactions section, Clinical studies section, Warnings and precautions section
    • source: U.S. Food and Drug Administration
  • familial hypercholesterolemia - homozygous
    • Use in specific populations section
    • source: U.S. Food and Drug Administration
  • APOE
    • other, Clinical studies section
    • source: U.S. Food and Drug Administration
  • LDLR
    • other, Clinical studies section, Use in specific populations section
    • source: U.S. Food and Drug Administration

last updated 09/01/2016

2. FDA Label for pravastatin and APOE

Informative PGx
Full label available at DailyMed

Genes and/or phenotypes found in this label


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for pravastatin

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA APOE E2 N/A N/A N/A
No VIP available CA No VIP available APOE E3 N/A N/A N/A
No VIP available CA VA APOE E4 N/A N/A N/A
No VIP available No VIP available VA SLCO1B1 *1 N/A N/A N/A
No VIP available CA VA SLCO1B1 *1A N/A N/A N/A
No VIP available CA No VIP available SLCO1B1 *1B N/A N/A N/A
No VIP available No VIP available VA SLCO1B1 *5 N/A N/A N/A
No VIP available CA VA SLCO1B1 *15 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs10255565
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available No Clinical Annotations available VA
rs10778228
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1079199
T > C
SNP
No VIP available No Clinical Annotations available VA
rs10907653
T > C
SNP
No VIP available No Clinical Annotations available VA
rs10971182
G > A
SNP
No VIP available No Clinical Annotations available VA
rs11157718
C > T
SNP
No VIP available No Clinical Annotations available VA
rs1116816
C > T
SNP
No VIP available CA VA
rs113646094 NC_000010.10:g.101564012C>G, NC_000010.11:g.99804255C>G, NG_011798.1:g.26550C>G, NM_000392.4:c.1446C>G, NP_000383.1:p.Thr482=, XM_005269536.1:c.1446C>G, XM_006717630.2:c.750C>G, XM_006717631.2:c.1446C>G, XM_011539291.1:c.1446C>G, XP_005269593.1:p.Thr482=, XP_006717693.1:p.Thr250=, XP_006717694.1:p.Thr482=, XP_011537593.1:p.Thr482=, XR_945604.1:n.1635C>G, XR_945605.1:n.1637C>G
C > G
SNP
T482T
No VIP available No Clinical Annotations available VA
rs1150226 NC_000011.10:g.113974819A>G, NC_000011.9:g.113845541A>G, NG_013058.1:g.4745A>G, NM_000869.5:c.-489A>G, NM_213621.3:c.-489A>G, NR_046363.1:n.-256A>G, rs1456890, rs1672729, rs386518532, rs56774067
A > G
SNP
No VIP available No Clinical Annotations available VA
rs11654492
A > C
SNP
No VIP available No Clinical Annotations available VA
rs11666735 NC_000019.10:g.54885501G=, NC_000019.10:g.54885501G>A, NC_000019.9:g.55396913G=, NC_000019.9:g.55396913G>A, NM_002000.3:c.337G=, NM_002000.3:c.337G>A, NM_133269.3:c.337G=, NM_133269.3:c.337G>A, NM_133271.3:c.337G=, NM_133271.3:c.337G>A, NM_133272.3:c.301G=, NM_133272.3:c.301G>A, NM_133273.3:c.301G=, NM_133273.3:c.301G>A, NM_133274.3:c.301G=, NM_133274.3:c.301G>A, NM_133277.3:c.35-2461A>G, NM_133277.3:c.35-2461G>A, NM_133277.3:c.35-2506A>G, NM_133277.3:c.35-2506G>A, NM_133278.3:c.301G=, NM_133278.3:c.301G>A, NM_133279.2:c.337G=, NM_133279.2:c.337G>A, NP_001991.1:p.Asp113=, NP_001991.1:p.Asp113Asn, NP_579803.1:p.Asp113=, NP_579803.1:p.Asp113Asn, NP_579805.1:p.Asp113=, NP_579805.1:p.Asp113Asn, NP_579806.1:p.Asp101=, NP_579806.1:p.Asp101Asn, NP_579807.1:p.Asp101=, NP_579807.1:p.Asp101Asn, NP_579808.1:p.Asp101=, NP_579808.1:p.Asp101Asn, NP_579812.1:p.Asp101=, NP_579812.1:p.Asp101Asn, NP_579813.1:p.Asp113=, NP_579813.1:p.Asp113Asn, NT_187671.1:g.164448G=, NT_187671.1:g.164448G>A, NT_187674.1:g.171521G=, NT_187674.1:g.171521G>A, NT_187675.1:g.255740G=, NT_187675.1:g.255740G>A, NT_187676.1:g.161451G=, NT_187676.1:g.161451G>A, NT_187677.1:g.162868G=, NT_187677.1:g.162868G>A, NT_187683.1:g.159719G=, NT_187683.1:g.159719G>A, NT_187693.1:g.868027G=, NT_187693.1:g.868027G>A, NW_003571055.1:g.530732A=, NW_003571055.1:g.530732A>G, NW_003571055.2:g.530733A=, NW_003571055.2:g.530733A>G, NW_003571060.1:g.789866G=, NW_003571060.1:g.789866G>A, NW_004166865.1:g.859869G=, NW_004166865.1:g.859869G>A, XM_011526625.1:c.256G=, XM_011526625.1:c.256G>A, XM_011526626.1:c.256G=, XM_011526626.1:c.256G>A, XM_011547517.1:c.256A=, XM_011547517.1:c.256A>G, XM_011547518.1:c.256A=, XM_011547518.1:c.256A>G, XM_011547519.1:c.71-2503A>G, XM_011547519.1:c.71-2503G>A, XM_011547554.1:c.256G=, XM_011547554.1:c.256G>A, XM_011547555.1:c.256G=, XM_011547555.1:c.256G>A, XM_011547562.1:c.256G=, XM_011547562.1:c.256G>A, XM_011547563.1:c.256G=, XM_011547563.1:c.256G>A, XM_011547566.1:c.256G=, XM_011547566.1:c.256G>A, XM_011547567.1:c.256G=, XM_011547567.1:c.256G>A, XM_011547573.1:c.256G=, XM_011547573.1:c.256G>A, XM_011547574.1:c.256G=, XM_011547574.1:c.256G>A, XM_011547578.1:c.256G=, XM_011547578.1:c.256G>A, XM_011547579.1:c.256G=, XM_011547579.1:c.256G>A, XM_011547803.1:c.256G=, XM_011547803.1:c.256G>A, XM_011547804.1:c.256G=, XM_011547804.1:c.256G>A, XM_011548553.1:c.256G=, XM_011548553.1:c.256G>A, XM_011548554.1:c.256G=, XM_011548554.1:c.256G>A, XM_011548697.1:c.256G=, XM_011548697.1:c.256G>A, XM_011548698.1:c.256G=, XM_011548698.1:c.256G>A, XM_011548699.1:c.71-2461A>G, XM_011548699.1:c.71-2461G>A, XP_011524927.1:p.Asp86=, XP_011524927.1:p.Asp86Asn, XP_011524928.1:p.Asp86=, XP_011524928.1:p.Asp86Asn, XP_011545819.1:p.Asn86=, XP_011545819.1:p.Asn86Asp, XP_011545820.1:p.Asn86=, XP_011545820.1:p.Asn86Asp, XP_011545856.1:p.Asp86=, XP_011545856.1:p.Asp86Asn, XP_011545857.1:p.Asp86=, XP_011545857.1:p.Asp86Asn, XP_011545864.1:p.Asp86=, XP_011545864.1:p.Asp86Asn, XP_011545865.1:p.Asp86=, XP_011545865.1:p.Asp86Asn, XP_011545868.1:p.Asp86=, XP_011545868.1:p.Asp86Asn, XP_011545869.1:p.Asp86=, XP_011545869.1:p.Asp86Asn, XP_011545875.1:p.Asp86=, XP_011545875.1:p.Asp86Asn, XP_011545876.1:p.Asp86=, XP_011545876.1:p.Asp86Asn, XP_011545880.1:p.Asp86=, XP_011545880.1:p.Asp86Asn, XP_011545881.1:p.Asp86=, XP_011545881.1:p.Asp86Asn, XP_011546105.1:p.Asp86=, XP_011546105.1:p.Asp86Asn, XP_011546106.1:p.Asp86=, XP_011546106.1:p.Asp86Asn, XP_011546855.1:p.Asp86=, XP_011546855.1:p.Asp86Asn, XP_011546856.1:p.Asp86=, XP_011546856.1:p.Asp86Asn, XP_011546999.1:p.Asp86=, XP_011546999.1:p.Asp86Asn, XP_011547000.1:p.Asp86=, XP_011547000.1:p.Asp86Asn, rs52806707
G > A
SNP
D113N
No VIP available No Clinical Annotations available VA
rs11709385
G > C
G > T
SNP
No VIP available CA VA
rs11716445 NC_000003.11:g.49406095G>A, NC_000003.12:g.49368662G>A, NM_001313941.1:c.157-114C>T, NM_001313943.1:c.157-114C>T, NM_001313944.1:c.130-147C>T, NM_001313945.1:c.-87-114C>T, NM_001313946.1:c.156+6772C>T, NM_001313947.1:c.157-6036C>T, NM_001664.3:c.157-114C>T, XM_005265116.1:c.130-147C>T, XM_011533695.1:c.157-114C>T, rs56548113, rs58714945
G > A
SNP
No VIP available CA VA
rs12003906 NC_000009.11:g.107645477G>T, NC_000009.12:g.104883196G>T, NG_007981.1:g.49960C>A, NM_005502.3:c.303-39C>A, XM_005251773.1:c.303-39C>A, XM_005251774.1:c.303-39C>A, XM_005251775.1:c.240-39C>A, XM_005251776.1:c.123-39C>A, XM_005251777.1:c.303-39C>A, XM_005251778.1:c.303-39C>A, XM_005251780.1:c.303-39C>A, XM_011518339.1:c.378-39C>A, XM_011518340.1:c.378-39C>A, XM_011518341.1:c.378-39C>A, XM_011518342.1:c.-61-39C>A, XM_011518343.1:c.378-39C>A, XM_011518344.1:c.378-39C>A, rs58402594
G > C
G > T
SNP
No VIP available No Clinical Annotations available VA
rs12501068
G > T
SNP
No VIP available No Clinical Annotations available VA
rs1271562
A > T
SNP
No VIP available No Clinical Annotations available VA
rs12725107
A > C
SNP
No VIP available No Clinical Annotations available VA
rs140700 NC_000017.10:g.28543389C>T, NC_000017.11:g.30216371C>T, NG_011747.2:g.24566G>A, NM_001045.5:c.838-155G>A, XM_005258025.1:c.964-155G>A, rs386530829, rs59205571
C > T
SNP
No VIP available CA VA
rs1433099 NC_000019.10:g.11131982T>C, NC_000019.9:g.11242658T>C, NG_009060.1:g.47602T>C, NM_000527.4:c.*666T>C, NM_001195798.1:c.*666T>C, NM_001195799.1:c.*666T>C, NM_001195800.1:c.*666T>C, NM_001195803.1:c.*666T>C, XM_005259909.1:c.*666T>C, XM_011528010.1:c.*666T>C, XM_011528011.1:c.*666T>C, rs17249043, rs61527870
T > C
SNP
No VIP available No Clinical Annotations available VA
rs1436260
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1440451 NC_000007.13:g.154868879G>C, NC_000007.14:g.155077169G>C, NG_044997.1:g.11846G>C, NM_024012.3:c.741+5529G>C, rs10321327, rs17837394, rs56554708, rs59321107, rs59745825
G > C
SNP
No VIP available No Clinical Annotations available VA
rs1519483
C > T
SNP
No VIP available No Clinical Annotations available VA
rs160919
G > A
SNP
No VIP available CA VA
rs16944 NC_000002.11:g.113594867A>G, NC_000002.12:g.112837290A>G, NG_008851.1:g.4490T>C, NM_000576.2:c.-598T>C, XM_006712496.1:c.-1552T>C, rs3827762
A > G
SNP
No VIP available No Clinical Annotations available VA
rs17120361
G > A
SNP
No VIP available No Clinical Annotations available VA
rs17222723 NC_000010.10:g.101595996T>A, NC_000010.11:g.99836239T>A, NG_011798.1:g.58534T>A, NM_000392.4:c.3563T>A, NP_000383.1:p.Val1188Glu, XM_005269536.1:c.3284T>A, XM_006717630.2:c.2867T>A, XP_005269593.1:p.Val1095Glu, XP_006717693.1:p.Val956Glu, XR_945604.1:n.3752T>A, XR_945605.1:n.3754T>A, rs52837755, rs59106280
T > A
SNP
V1188E
No VIP available No Clinical Annotations available VA
rs17223074
C > T
SNP
rs17238540 NC_000005.10:g.75359673T>G, NC_000005.9:g.74655498T>G, NG_011449.1:g.27506T>G, NM_000859.2:c.2457+117T>G, NM_001130996.1:c.2298+117T>G, XM_005248492.1:c.2517+117T>G, XM_011543357.1:c.2517+117T>G, XM_011543358.1:c.2457+117T>G, XM_011543359.1:c.2358+117T>G, rs59500163
T > G
SNP
rs17244841 NC_000005.10:g.75347030A>T, NC_000005.9:g.74642855A>T, NG_011449.1:g.14863A>T, NM_000859.2:c.451-174A>T, NM_001130996.1:c.451-174A>T, XM_005248492.1:c.511-174A>T, XM_011543357.1:c.511-174A>T, XM_011543358.1:c.451-174A>T, XM_011543359.1:c.511-174A>T, rs60168925
A > T
SNP
No VIP available No Clinical Annotations available VA
rs17633730
G > T
SNP
No VIP available CA VA
rs17655652 NC_000007.13:g.44580991T>C, NC_000007.14:g.44541392T>C, NG_013088.1:g.4924A>G, NM_001101648.1:c.-133A>G, NM_001300967.1:c.-133A>G, NM_013389.2:c.-133A>G, XM_005249723.1:c.-133A>G, XM_011515326.1:c.-133A>G, XM_011515327.1:c.-133A>G, rs58496691
T > C
SNP
No VIP available CA VA
rs1799752 NC_000017.10:g.61565890_61565891insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NC_000017.10:g.61565890_61565891insG, NC_000017.11:g.63488529_63488530insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NC_000017.11:g.63488529_63488530insG, NG_011648.1:g.16457_16458insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NG_011648.1:g.16457_16458insG, NM_000789.3:c.2306-119_2306-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_000789.3:c.2306-119_2306-118insG, NM_001178057.1:c.584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_001178057.1:c.584-119_584-118insG, NM_152830.2:c.584-119_584-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, NM_152830.2:c.584-119_584-118insG, XM_005257110.1:c.1757-119_1757-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, XM_005257110.1:c.1757-119_1757-118insG, XM_006721737.2:c.644-119_644-118insATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC, XM_006721737.2:c.644-119_644-118insG
- > ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC
- > G
indel
No VIP available CA VA
rs1800588 NC_000015.10:g.58431476C>T, NC_000015.9:g.58723675C>T, NG_011465.1:g.4501C>T, NM_000236.2:c.-557C>T, XM_005254372.1:c.-40-517C>T, XM_005254373.1:c.-40-517C>T, XM_011521551.1:c.-40-517C>T, XR_429537.2:n.-124G>A, XR_932289.1:n.-124G>A, rs52833592
C > T
SNP
No VIP available CA VA
rs1800591 NC_000004.11:g.100495488G>T, NC_000004.12:g.99574331G>T, NG_011469.1:g.15249G>T, NM_000253.3:c.-101-478G>T, NM_001300785.1:c.143-7574G>T, XM_005263025.1:c.143-7574G>T, rs17598205
G > T
SNP
No VIP available No Clinical Annotations available VA
rs1801131 NC_000001.10:g.11854476T>G, NC_000001.11:g.11794419T>G, NG_013351.1:g.16685A>C, NM_005957.4:c.1286A>C, NP_005948.3:p.Glu429Ala, XM_005263458.1:c.1409A>C, XM_005263458.2:c.1409A>C, XM_005263459.1:c.1355A>C, XM_005263460.1:c.1286A>C, XM_005263460.3:c.1286A>C, XM_005263461.1:c.1286A>C, XM_005263461.3:c.1286A>C, XM_005263462.1:c.1286A>C, XM_005263462.3:c.1286A>C, XM_005263463.1:c.1040A>C, XM_005263463.2:c.1040A>C, XM_011541495.1:c.1406A>C, XM_011541496.1:c.1409A>C, XP_005263515.1:p.Glu470Ala, XP_005263516.1:p.Glu452Ala, XP_005263517.1:p.Glu429Ala, XP_005263518.1:p.Glu429Ala, XP_005263519.1:p.Glu429Ala, XP_005263520.1:p.Glu347Ala, XP_011539797.1:p.Glu469Ala, XP_011539798.1:p.Glu470Ala, rs17367365, rs17857426, rs4134712
T > G
SNP
E429A
No VIP available CA VA
rs1801133 NC_000001.10:g.11856378G>A, NC_000001.11:g.11796321G>A, NG_013351.1:g.14783C>T, NM_005957.4:c.665C>T, NP_005948.3:p.Ala222Val, XM_005263458.1:c.788C>T, XM_005263458.2:c.788C>T, XM_005263459.1:c.734C>T, XM_005263460.1:c.665C>T, XM_005263460.3:c.665C>T, XM_005263461.1:c.665C>T, XM_005263461.3:c.665C>T, XM_005263462.1:c.665C>T, XM_005263462.3:c.665C>T, XM_005263463.1:c.419C>T, XM_005263463.2:c.419C>T, XM_011541495.1:c.785C>T, XM_011541496.1:c.788C>T, XP_005263515.1:p.Ala263Val, XP_005263516.1:p.Ala245Val, XP_005263517.1:p.Ala222Val, XP_005263518.1:p.Ala222Val, XP_005263519.1:p.Ala222Val, XP_005263520.1:p.Ala140Val, XP_011539797.1:p.Ala262Val, XP_011539798.1:p.Ala263Val, rs386545618, rs4134713, rs59514310
G > A
SNP
A222V
No VIP available No Clinical Annotations available VA
rs1805054 NC_000001.10:g.19992513C>T, NC_000001.11:g.19666020C>T, NM_000871.2:c.267C>T, NP_000862.1:p.Tyr89=, rs58500287
C > T
SNP
Y89Y
No VIP available No Clinical Annotations available VA
rs1885155
A > C
SNP
No VIP available No Clinical Annotations available VA
rs1891311 NC_000010.10:g.92618616A>G, NC_000010.11:g.90858859A>G, NG_029218.1:g.4056T>C, NM_000872.4:c.-1188T>C, NM_019859.3:c.-1188T>C, NM_019860.3:c.-1188T>C, rs3824740, rs60062136
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1913896
C > T
SNP
No VIP available CA VA
rs1935349 NC_000010.10:g.92594343C>T, NC_000010.11:g.90834586C>T, NG_029218.1:g.28329G>A, NM_000872.4:c.539+22547G>A, NM_019859.3:c.539+22547G>A, NM_019860.3:c.539+22547G>A, rs60894291
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2020933 NC_000017.10:g.28561755A>T, NC_000017.11:g.30234737A>T, NG_011747.2:g.6200T>A, NM_001045.5:c.-221+876T>A, XM_005258025.1:c.-95+876T>A, rs58019660
A > T
SNP
No VIP available CA VA
rs2032582 NC_000007.13:g.87160618A>C, NC_000007.13:g.87160618A>T, NC_000007.14:g.87531302A>C, NC_000007.14:g.87531302A>T, NG_011513.1:g.186947T>A, NG_011513.1:g.186947T>G, NM_000927.4:c.2677T>A, NM_000927.4:c.2677T>G, NP_000918.2:p.Ser893Ala, NP_000918.2:p.Ser893Thr, rs10228331, rs2229106, rs386553610, rs57135550, rs9641018
A > C
SNP
S893A
No VIP available CA VA
rs20455 NC_000006.11:g.39325078A>G, NC_000006.12:g.39357302A>G, NM_001289020.1:c.2104T>C, NM_001289021.1:c.1987T>C, NM_001289024.1:c.508T>C, NM_145027.4:c.2155T>C, NP_001275949.1:p.Trp702Arg, NP_001275950.1:p.Trp663Arg, NP_001275953.1:p.Trp170Arg, NP_659464.3:p.Trp719Arg, XM_005248904.1:c.2155T>C, XM_005248904.3:c.2155T>C, XM_005248905.1:c.2104T>C, XM_005248906.1:c.1987T>C, XM_011514357.1:c.2155T>C, XM_011514358.1:c.2155T>C, XM_011514359.1:c.2155T>C, XM_011514360.1:c.1528T>C, XP_005248961.1:p.Trp719Arg, XP_005248962.1:p.Trp702Arg, XP_005248963.1:p.Trp663Arg, XP_011512659.1:p.Trp719Arg, XP_011512660.1:p.Trp719Arg, XP_011512661.1:p.Trp719Arg, XP_011512662.1:p.Trp510Arg, rs16891985, rs56572561, rs58306844
A > G
SNP
W702R
No VIP available CA VA
rs2230806 NC_000009.11:g.107620867C>T, NC_000009.12:g.104858586C>T, NG_007981.1:g.74570G>A, NM_005502.3:c.656G>A, NP_005493.2:p.Arg219Lys, XM_005251773.1:c.656G>A, XM_005251774.1:c.656G>A, XM_005251775.1:c.593G>A, XM_005251776.1:c.476G>A, XM_005251777.1:c.656G>A, XM_005251778.1:c.656G>A, XM_005251780.1:c.656G>A, XM_011518339.1:c.731G>A, XM_011518340.1:c.731G>A, XM_011518341.1:c.731G>A, XM_011518342.1:c.293G>A, XM_011518343.1:c.731G>A, XM_011518344.1:c.731G>A, XP_005251830.1:p.Arg219Lys, XP_005251831.1:p.Arg219Lys, XP_005251832.1:p.Arg198Lys, XP_005251833.1:p.Arg159Lys, XP_005251834.1:p.Arg219Lys, XP_005251835.1:p.Arg219Lys, XP_005251837.1:p.Arg219Lys, XP_011516641.1:p.Arg244Lys, XP_011516642.1:p.Arg244Lys, XP_011516643.1:p.Arg244Lys, XP_011516644.1:p.Arg98Lys, XP_011516645.1:p.Arg244Lys, XP_011516646.1:p.Arg244Lys, rs2234884, rs2853572, rs52801000, rs61696010
C > T
SNP
R219K
No VIP available No Clinical Annotations available VA
rs2231137 NC_000004.11:g.89061114C>T, NC_000004.12:g.88139962C>T, NG_032067.2:g.96361G>A, NM_001257386.1:c.34G>A, NM_004827.2:c.34G>A, NP_001244315.1:p.Val12Met, NP_004818.2:p.Val12Met, XM_005263354.1:c.34G>A, XM_005263354.2:c.34G>A, XM_005263355.1:c.34G>A, XM_005263355.2:c.34G>A, XM_005263356.1:c.34G>A, XM_005263356.2:c.34G>A, XM_011532420.1:c.34G>A, XP_005263411.1:p.Val12Met, XP_005263412.1:p.Val12Met, XP_005263413.1:p.Val12Met, XP_011530722.1:p.Val12Met
C > T
SNP
V12M
No VIP available No Clinical Annotations available VA
rs2231142 NC_000004.11:g.89052323G>T, NC_000004.12:g.88131171G>T, NG_032067.2:g.105152C>A, NM_001257386.1:c.421C>A, NM_004827.2:c.421C>A, NP_001244315.1:p.Gln141Lys, NP_004818.2:p.Gln141Lys, XM_005263354.1:c.421C>A, XM_005263354.2:c.421C>A, XM_005263355.1:c.421C>A, XM_005263355.2:c.421C>A, XM_005263356.1:c.421C>A, XM_005263356.2:c.421C>A, XM_011532420.1:c.421C>A, XP_005263411.1:p.Gln141Lys, XP_005263412.1:p.Gln141Lys, XP_005263413.1:p.Gln141Lys, XP_011530722.1:p.Gln141Lys, rs12721641, rs28365035, rs3736117, rs52809243, rs58973676
G > T
SNP
Q141K
No VIP available No Clinical Annotations available VA
rs2273697 NC_000010.10:g.101563815G>A, NC_000010.11:g.99804058G>A, NG_011798.1:g.26353G>A, NM_000392.4:c.1249G>A, NP_000383.1:p.Val417Ile, XM_005269536.1:c.1249G>A, XM_006717630.2:c.553G>A, XM_006717631.2:c.1249G>A, XM_011539291.1:c.1249G>A, XP_005269593.1:p.Val417Ile, XP_006717693.1:p.Val185Ile, XP_006717694.1:p.Val417Ile, XP_011537593.1:p.Val417Ile, XR_945604.1:n.1438G>A, XR_945605.1:n.1440G>A, rs17216184, rs60620335
G > A
SNP
V417I
No VIP available CA VA
rs2276307 NC_000011.10:g.113933165A>G, NC_000011.9:g.113803887A>G, NG_011483.1:g.33299A>G, NM_006028.4:c.696+72A>G, XM_011543063.1:c.663+72A>G, XM_011543064.1:c.495+72A>G, XM_011543065.1:c.489+72A>G, XM_011543066.1:c.663+72A>G, rs60179104
A > G
SNP
rs2306283 NC_000012.11:g.21329738A>G, NC_000012.12:g.21176804A>G, NG_011745.1:g.50611A>G, NM_006446.4:c.388A>G, NP_006437.3:p.Asn130Asp, rs17389242, rs52832430, rs60767041
A > G
SNP
N130D
No VIP available No Clinical Annotations available VA
rs271828
C > A
SNP
No VIP available CA VA
rs2738466 NC_000019.10:g.11132089A>G, NC_000019.9:g.11242765A>G, NG_009060.1:g.47709A>G, NM_000527.4:c.*773A>G, NM_001195798.1:c.*773A>G, NM_001195799.1:c.*773A>G, NM_001195800.1:c.*773A>G, NM_001195803.1:c.*773A>G, XM_005259909.1:c.*773A>G, XM_011528010.1:c.*773A>G, XM_011528011.1:c.*773A>G, rs17249050, rs17766424, rs56908144
A > G
SNP
No VIP available No Clinical Annotations available VA
rs2791188
A > G
SNP
No VIP available No Clinical Annotations available VA
rs281018
C > T
SNP
No VIP available CA VA
rs3025058 NC_000011.9:g.102715948_102715949insA, NG_012100.1:g.3394_3395insT, NM_002422.4:c.-1672_-1671insT, NW_003871077.1:g.13452_13453insA, rs144886253, rs61423715, rs66847152, rs66847153, rs72520913, rs72562167
- > A
indel
No VIP available No Clinical Annotations available VA
rs306468
A > T
SNP
No VIP available No Clinical Annotations available VA
rs3172494
G > T
SNP
No VIP available CA VA
rs328 NC_000008.10:g.19819724C>G, NC_000008.11:g.19962213C>G, NG_008855.1:g.28143C>G, NM_000237.2:c.1421C>G, NP_000228.1:p.Ser474Ter, rs17482566, rs3735962, rs52834251
C > G
SNP
S474*
No VIP available No Clinical Annotations available VA
rs352887
A > G
SNP
No VIP available No Clinical Annotations available VA
rs3758987 NC_000011.10:g.113904553T>C, NC_000011.9:g.113775275T>C, NG_011483.1:g.4687T>C, NM_006028.4:c.-381T>C, XM_011543064.1:c.12+5470T>C, rs17542553, rs386585621, rs60662070
T > C
SNP
VIP No Clinical Annotations available No Variant Annotations available
rs3846662 NC_000005.10:g.75355259A>G, NC_000005.9:g.74651084A>G, NG_011449.1:g.23092A>G, NM_000859.2:c.1722+45A>G, NM_001130996.1:c.1564-106A>G, XM_005248492.1:c.1782+45A>G, XM_011543357.1:c.1782+45A>G, XM_011543358.1:c.1722+45A>G, XM_011543359.1:c.1624-106A>G, rs17238505, rs17562582, rs386587624, rs56538861, rs59397732
A > G
SNP
No VIP available No Clinical Annotations available VA
rs3934874
G > A
SNP
rs4149015 NC_000012.11:g.21283322G>A, NC_000012.12:g.21130388G>A, NG_011745.1:g.4195G>A, NM_006446.4:c.-910G>A
G > A
SNP
rs4149056 NC_000012.11:g.21331549T>C, NC_000012.12:g.21178615T>C, NG_011745.1:g.52422T>C, NM_006446.4:c.521T>C, NP_006437.3:p.Val174Ala, rs52816141, rs60037639
T > C
SNP
V174A
No VIP available CA VA
rs428785 NC_000021.8:g.28216595C>G, NC_000021.9:g.26844276C>G, NM_006988.4:c.679G>C, NP_008919.3:p.Ala227Pro, rs17857114
C > G
SNP
A227P
No VIP available CA VA
rs4341 NC_000017.10:g.61565990G>C, NC_000017.11:g.63488629G>C, NG_011648.1:g.16557G>C, NM_000789.3:c.2306-19G>C, NM_001178057.1:c.584-19G>C, NM_152830.2:c.584-19G>C, XM_005257110.1:c.1757-19G>C, XM_006721737.2:c.644-19G>C, rs17442272, rs59314714
G > C
SNP
No VIP available No Clinical Annotations available VA
rs453359
A > C
SNP
No VIP available No Clinical Annotations available VA
rs4693075 NC_000004.11:g.84192168G>C, NC_000004.12:g.83271015G>C, NG_015825.1:g.18900C>G, NM_015697.7:c.779-1022C>G, XM_005262926.1:c.425-1022C>G, XM_005262927.1:c.299-1022C>G, XM_011531855.1:c.779-1022C>G, XM_011531856.1:c.779-1022C>G, XM_011531857.1:c.779-1022C>G, XM_011531858.1:c.779-1022C>G, XM_011531859.1:c.779-1022C>G, XM_011531860.1:c.779-1022C>G, XM_011531861.1:c.779-1022C>G, XM_011531862.1:c.779-1022C>G, XM_011531863.1:c.779-1022C>G, XM_011531864.1:c.779-1022C>G, XM_011531865.1:c.779-1022C>G, XM_011531866.1:c.779-1022C>G, XM_011531867.1:c.425-1022C>G, XR_427543.2:n.938-1022C>G, XR_938721.1:n.949-1022C>G, rs58141687
G > C
SNP
No VIP available No Clinical Annotations available VA
rs4767452
T > C
SNP
A290A
No VIP available CA VA
rs4986790 NC_000009.11:g.120475302A>G, NC_000009.12:g.117713024A>G, NG_011475.1:g.13843A>G, NM_003266.3:c.776A>G, NM_138554.3:c.896A>G, NM_138554.4:c.896A>G, NM_138557.2:c.296A>G, NP_003257.1:p.Asp259Gly, NP_612564.1:p.Asp299Gly, NP_612567.1:p.Asp99Gly, XM_005252182.1:c.890A>G, XP_005252239.1:p.Asp297Gly, rs52820966, rs59093760
A > G
SNP
D259G
No VIP available No Clinical Annotations available VA
rs4986791 NC_000009.11:g.120475602C>T, NC_000009.12:g.117713324C>T, NG_011475.1:g.14143C>T, NM_003266.3:c.1076C>T, NM_138554.3:c.1196C>T, NM_138554.4:c.1196C>T, NM_138557.2:c.596C>T, NP_003257.1:p.Thr359Ile, NP_612564.1:p.Thr399Ile, NP_612567.1:p.Thr199Ile, XM_005252182.1:c.1190C>T, XP_005252239.1:p.Thr397Ile, rs52826331
C > T
SNP
T359I
No VIP available No Clinical Annotations available VA
rs502114
A > T
SNP
No VIP available No Clinical Annotations available VA
rs539748 NC_000023.10:g.113821349T=, NC_000023.10:g.113821349T>C, NC_000023.11:g.114586876C>T, NG_012082.2:g.7792C=, NG_012082.2:g.7792C>T, NM_000868.3:c.-147+2217C>T, NM_000868.3:c.-147+2217T>C, NM_001256760.2:c.-238+2217C>T, NM_001256760.2:c.-238+2217T>C, NM_001256761.2:c.-147+2217C>T, NM_001256761.2:c.-147+2217T>C, NW_004070891.1:g.255678C=, NW_004070891.1:g.255678C>T, rs17260551, rs56834670
T > C
SNP
No VIP available No Clinical Annotations available VA
rs6312 NC_000013.10:g.47470824C>T, NC_000013.11:g.46896689C>T, NG_013011.1:g.5346G>A, NM_000621.4:c.-344G>A, NM_001165947.2:c.145G>A, NP_001159419.1:p.Asp49Asn, rs17289199, rs36212450, rs60357050
C > T
SNP
D49N
No VIP available No Clinical Annotations available VA
rs6318 NC_000023.10:g.113965735G=, NC_000023.10:g.113965735G>C, NC_000023.11:g.114731326C=, NC_000023.11:g.114731326C>G, NG_012082.2:g.152242G=, NG_012082.2:g.152242G>C, NM_000868.3:c.68G=, NM_000868.3:c.68G>C, NM_001256760.2:c.68G=, NM_001256760.2:c.68G>C, NM_001256761.2:c.68G=, NM_001256761.2:c.68G>C, NP_000859.1:p.Cys23=, NP_000859.1:p.Cys23Ser, NP_001243689.1:p.Cys23=, NP_001243689.1:p.Cys23Ser, NP_001243690.1:p.Cys23=, NP_001243690.1:p.Cys23Ser, NW_004070891.1:g.400128C=, NW_004070891.1:g.400128C>G, XR_944300.1:n.209-550C>G, XR_944300.1:n.209-550G>C, XR_944301.1:n.209-550C>G, XR_944301.1:n.209-550G>C
G > C
SNP
C23S
No VIP available No Clinical Annotations available VA
rs6475859
A > C
SNP
No VIP available No Clinical Annotations available VA
rs655130
T > C
SNP
No VIP available No Clinical Annotations available VA
rs659734 NC_000013.10:g.47435283G>A, NC_000013.11:g.46861148G>A, NG_013011.1:g.40887C>T, NM_000621.4:c.614-25509C>T, NM_001165947.2:c.362-25509C>T, rs17359936, rs386603779, rs59168055
G > A
SNP
No VIP available No Clinical Annotations available VA
rs6601319
T > C
SNP
No VIP available No Clinical Annotations available VA
rs670 NC_000011.10:g.116837697C>T, NC_000011.9:g.116708413C>T, NG_012021.1:g.4926G>A, NM_000039.2:c.-113G>A, NM_001318017.1:c.-190G>A, NM_001318018.1:c.-159G>A, NM_001318021.1:c.-396G>A, NR_126362.1:n.123+1458C>T, XM_005271539.1:c.-159G>A, XM_005271539.2:c.-159G>A, XM_005271540.1:c.-190G>A, rs17243116, rs61758319
C > T
SNP
No VIP available No Clinical Annotations available VA
rs676643 NC_000001.10:g.23521340G>A, NC_000001.11:g.23194847G>A, NM_000864.4:c.-628C>T, rs3753253, rs386604973, rs61725275
G > A
SNP
No VIP available No Clinical Annotations available VA
rs6894567
A > G
SNP
No VIP available CA VA
rs708272 NC_000016.10:g.56962376G>A, NC_000016.9:g.56996288G>A, NG_008952.1:g.5454G>A, NM_000078.2:c.118+279G>A, NM_001286085.1:c.118+279G>A, XM_005255776.1:c.118+279G>A, XM_006721124.2:c.118+279G>A, rs17237904, rs17290342, rs57207652
G > A
SNP
No VIP available No Clinical Annotations available VA
rs7102569
A > G
SNP
No VIP available No Clinical Annotations available VA
rs7135770
T > C
SNP
No VIP available No Clinical Annotations available VA
rs7242734
G > T
SNP
No VIP available No Clinical Annotations available VA
rs7412 NC_000019.10:g.44908822C>T, NC_000019.9:g.45412079C>T, NG_007084.2:g.8041C>T, NM_000041.3:c.526C>T, NM_001302688.1:c.604C>T, NM_001302689.1:c.526C>T, NM_001302690.1:c.526C>T, NM_001302691.1:c.526C>T, NP_000032.1:p.Arg176Cys, NP_001289617.1:p.Arg202Cys, NP_001289618.1:p.Arg176Cys, NP_001289619.1:p.Arg176Cys, NP_001289620.1:p.Arg176Cys, XM_005258867.1:c.604C>T, XM_005258868.1:c.526C>T, XP_005258924.1:p.Arg202Cys, XP_005258925.1:p.Arg176Cys, rs3200542
C > T
SNP
R176C
No VIP available No Clinical Annotations available VA
rs776746 NC_000007.13:g.99270539C>T, NC_000007.14:g.99672916T>C, NG_007938.1:g.12083G=, NG_007938.1:g.12083G>A, NM_000777.4:c.219-237A>G, NM_000777.4:c.219-237G>A, NM_001190484.2:c.219-237A>G, NM_001190484.2:c.219-237G>A, NM_001291829.1:c.-253-1A>G, NM_001291829.1:c.-253-1G>A, NM_001291830.1:c.189-237A>G, NM_001291830.1:c.189-237G>A, NR_033807.2:n.717-1A>G, NR_033807.2:n.717-1G>A, NR_033808.1:n.689-1G>A, NR_033809.1:n.581-237G>A, NR_033810.1:n.689-1G>A, NR_033811.1:n.321-1G>A, NR_033812.1:n.321-1G>A, XM_005250169.1:c.189-237G>A, XM_005250170.1:c.-357-1G>A, XM_005250171.1:c.-253-1G>A, XM_005250172.1:c.-254G>A, XM_005250173.1:c.-331-237G>A, XM_005250198.1:c.806-4288C>T, XM_006715859.2:c.219-237A>G, XM_011515843.1:c.-254A>G, XM_011515844.1:c.-229-237A>G, XM_011515845.1:c.-463-1A>G, XM_011515846.1:c.-331-237A>G, XM_011515847.1:c.-571-1A>G, XR_927383.1:n.344-237A>G, XR_927402.1:n.1466+48736T>C, rs10361242, rs11266830, rs386613022, rs58244770
C > T
SNP
No VIP available No Clinical Annotations available VA
rs7870226
A > G
SNP
No VIP available No Clinical Annotations available VA
rs7927570
T > G
SNP
No VIP available No Clinical Annotations available VA
rs8014194 NC_000014.8:g.95720678T>A, NC_000014.9:g.95254341T>A, NM_024734.3:c.83-24208A>T, XM_005268064.1:c.83-24208A>T, XM_005268065.1:c.83-24208A>T, XM_011537158.1:c.83-24208A>T, XM_011537159.1:c.83-24208A>T, XR_245721.1:n.195-24208A>T, XR_245721.2:n.195-24208A>T, XR_245722.1:n.195-24208A>T, XR_429330.2:n.195-24208A>T, XR_429332.2:n.195-24208A>T, rs57153875
T > A
SNP
No VIP available No Clinical Annotations available VA
rs8092360
C > T
SNP
No VIP available No Clinical Annotations available VA
rs8187710 NC_000010.10:g.101611294G>A, NC_000010.11:g.99851537G>A, NG_011798.1:g.73832G>A, NM_000392.4:c.4544G>A, NP_000383.1:p.Cys1515Tyr, XM_005269536.1:c.4265G>A, XM_006717630.2:c.3848G>A, XP_005269593.1:p.Cys1422Tyr, XP_006717693.1:p.Cys1283Tyr, XR_945605.1:n.4608G>A, rs17222568, rs52804507, rs58135906
G > A
SNP
C1515Y
No VIP available No Clinical Annotations available VA
rs868589
T > C
SNP
No VIP available No Clinical Annotations available VA
rs9462535 NC_000006.11:g.39315792C>A, NC_000006.12:g.39348016C>A, NM_001289020.1:c.2130-1490G>T, NM_001289021.1:c.2013-1490G>T, NM_001289024.1:c.534-1490G>T, NM_145027.4:c.2181-1490G>T, XM_005248904.1:c.2181-1490G>T, XM_005248904.3:c.2181-1490G>T, XM_005248905.1:c.2130-1490G>T, XM_005248906.1:c.2013-1490G>T, XM_011514357.1:c.2181-2227G>T, XM_011514358.1:c.2181-1490G>T, XM_011514359.1:c.2181-2227G>T, XM_011514360.1:c.1554-1490G>T, rs58517045
C > A
SNP
No VIP available No Clinical Annotations available VA
rs9471077 NC_000006.11:g.39308742A>G, NC_000006.12:g.39340966A>G, NM_001289020.1:c.2377+2743T>C, NM_001289021.1:c.2260+2743T>C, NM_001289024.1:c.781+2743T>C, NM_145027.4:c.2428+2743T>C, XM_005248905.1:c.2377+2743T>C, XM_005248906.1:c.2260+2743T>C, XM_011514359.1:c.2377+2743T>C, XR_926774.1:n.239-1673A>G, rs59843364
A > G
SNP
No VIP available No Clinical Annotations available VA
rs9545683
C > T
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Pravastatin Sodium
  • Pravastatina [Spanish]
  • Pravastatine [French]
  • Pravastatinum [Latin]
Trade Names
  • Compactin
  • Elisor
  • Lipostat
  • Mevalotin
  • Mevastatin
  • Mevinolin
  • Oliprevin
  • Pravachol
  • Pravaselect
  • Selectin
  • Selipran
  • Vasten
Brand Mixture Names

PharmGKB Accession Id

PA451089

Type(s):

Drug

Description

Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered. It is a ring-opened dihydroxyacid with a 6'-hydroxyl group that does not require in vivo activation. Pravastatin is one of the lower potency statins; however, its increased hydrophilicity is thought to confer advantages such as minimal penetration through lipophilic membranes of peripheral cells, increased selectivity for hepatic tissues, and a reduction in side effects compared with lovastatin and simvastatin.

Source: Drug Bank

Indication

For the treatment of hypercholesterolemia and to reduce the risk of cardiovascular disease.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Pravastatin is structurally similar to the HMG, a substituent of the endogenous substrate of HMG-CoA reductase. Unlike its parent compound, mevastatin, and statins such as lovastatin and simvastatin, pravastatin does not need to be activated in vivo. Its hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase allowing the agent to bind with a much greater affinity than its natural substrate. The bicyclic portion of pravastatin binds to the coenzyme A portion of the active site.

Source: Drug Bank

Pharmacology

The primary cause of cardiovascular (CV) disease is atherosclerotic plaque formation and sustained elevation of cholesterol in the blood increases the risk of CV disease. Pravastatin lowers hepatic production of cholesterol by competitively inhibiting HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in the cholesterol biosynthesis pathway via the mevalonic acid pathway. Decreased hepatic cholesterol levels causes increased uptake of low density lipoprotein (LDL) cholesterol and reduces cholesterol levels in the circulation. Pravastatin also inhibits hepatic synthesis if VLDL. At therapeutic doses, pravastatin lowers LDL cholesterol by 20-30%, increase high density lipoprotein (HDL) cholesterol by 3-10%, and decrease plasma triglycerides by 19-34%. HDL cholesterol is thought to confer protective effects against CV disease, whereas high LDL and triglyceride levels are associated with higher risk of disease.

Source: Drug Bank

Food Interaction

Avoid alcohol.|Take without regard to meals.|Avoid drastic changes in dietary habit.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic, there is a small amount of metabolism by P450 enzymes, but this effect is so minimal that inhibitory pharmacokinetic drug interactions have no real effect on its overall activity and elimination. An in vitro study which found moderate affinity for P450 2C9 (major), 2D6 and 3A4.

Source: Drug Bank

Protein Binding

50%

Source: Drug Bank

Absorption

Average oral absorption of pravastatin is 34% and absolute bioavailability is 17%.

Source: Drug Bank

Half-Life

77 hours

Source: Drug Bank

Toxicity

Side effects include diarrhea, nausea, constipation, gas abdominal pain, myopathy, myositis, rhabdomyolysis, and hepatotoxicity. LD 50=mg/kg (orally in rat)

Source: Drug Bank

Route of Elimination

Approximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces.

Source: Drug Bank

Chemical Properties

Chemical Formula

C23H36O7

Source: Drug Bank

Isomeric SMILES

CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](CC(CC(=O)O)O)O)O

Source: OpenEye

Canonical SMILES

CC[C@H](C)C(=O)O[C@H]

Source: Drug Bank

Average Molecular Weight

424.5277

Source: Drug Bank

Monoisotopic Molecular Weight

424.246103506

Source: Drug Bank

SMILES

[H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC

Source: Drug Bank

InChI String

InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Ibuprofen Pathway, Pharmacokinetics
    Stylized diagram of metabolism and transport of ibuprofen in the liver and kidney.
  1. Pravastatin Pathway, Pharmacokinetics
    Drug-specific representation of the candidate genes involved in transport, metabolism and clearance.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ABCC2 (source: Drug Bank )
HMGCR (source: Drug Bank )
PGGT1B (source: Drug Bank )
RAC1 (source: Drug Bank )
SLCO1B1 (source: Drug Bank )

Curated Information ?

EvidenceDrug
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ibuprofen

Drug Interactions

Interaction Description
colchicine - pravastatin Increased risk of rhabdomyolysis with this combination (source: Drug Bank )
colchicine - pravastatin Increased risk of rhabdomyolysis with this combination (source: Drug Bank )
cyclosporine - pravastatin Possible myopathy and rhabdomyolysis (source: Drug Bank )
cyclosporine - pravastatin Possible myopathy and rhabdomyolysis (source: Drug Bank )
fenofibrate - pravastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank )
fenofibrate - pravastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank )
gemfibrozil - pravastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank )
gemfibrozil - pravastatin Increased risk of myopathy/rhabdomyolysis (source: Drug Bank )
pravastatin - bezafibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank )
pravastatin - bezafibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank )
pravastatin - colchicine Increased risk of rhabdomyolysis with this combination (source: Drug Bank )
pravastatin - colchicine Increased risk of rhabdomyolysis with this combination (source: Drug Bank )
pravastatin - cyclosporine Possible myopathy and rhabdomyolysis (source: Drug Bank )
pravastatin - cyclosporine Possible myopathy and rhabdomyolysis (source: Drug Bank )
pravastatin - fenofibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank )
pravastatin - fenofibrate Increased risk of myopathy/rhabdomyolysis (source: Drug Bank )
pravastatin - gemfibrozil Increased risk of myopathy/rhabdomyolysis (source: Drug Bank )
pravastatin - gemfibrozil Increased risk of myopathy/rhabdomyolysis (source: Drug Bank )
tipranavir - pravastatin Tipranavir may increase the plasma concentration of Pravastatin. Consider alternate therapy. (source: Drug Bank )

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Contraindicated With

Publications related to pravastatin: 99

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. Clinical pharmacokinetics. 2015. Mooij Miriam G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms and assessment of statin-related muscular adverse effects. British journal of clinical pharmacology. 2014. Moßhammer Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
In search for genetic determinants of clinically meaningful differential cardiovascular event reduction by pravastatin in the PHArmacogenetic study of Statins in the Elderly at risk (PHASE)/PROSPER study. Atherosclerosis. 2014. Postmus Iris, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof of Concept Study Using the Clinical Practice Research Datalink (CPRD). Clinical pharmacology and therapeutics. 2013. Carr Daniel F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
RHOA Is a Modulator of the Cholesterol-Lowering Effects of Statin. PLoS genetics. 2012. Medina Marisa W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Added value of pharmacogenetic testing in predicting statin response: results from the REGRESS trial. The pharmacogenomics journal. 2012. van der Baan F H, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The effects of a SNP in SLCO1B1 on the pharmacodynamics of pravastatin. British journal of clinical pharmacology. 2011. Martin Nicholas G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Detecting Drug Interactions From Adverse-Event Reports: Interaction Between Paroxetine and Pravastatin Increases Blood Glucose Levels. Clinical pharmacology and therapeutics. 2011. Tatonetti N P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011. Roden Dan M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clinical pharmacology and therapeutics. 2011. Sadee W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: methotrexate pathway. Pharmacogenetics and genomics. 2011. Mikkelsen Torben S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB: very important pharmacogene--HMGCR. Pharmacogenetics and genomics. 2011. Medina Marisa Wong, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variants in the KIF6 region and coronary event reduction from statin therapy. Human genetics. 2011. Li Yonghong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics. 2011. Becquemont Laurent, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Replication of LDL GWAs hits in PROSPER/PHASE as validation for future (pharmaco)genetic analyses. BMC medical genetics. 2011. Trompet Stella, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
KIF6 Trp719Arg polymorphism and the effect of statin therapy in elderly patients: results from the PROSPER study. European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. 2010. Iakoubova Olga A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer prevention research (Philadelphia, Pa.). 2010. Lipkin Steven M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variation at the NPC1L1 gene locus, plasma lipoproteins, and heart disease risk in the elderly. Journal of lipid research. 2010. Polisecki Eliana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of pravastatin therapy on coronary events in carriers of the KIF6 719Arg allele from the cholesterol and recurrent events trial. The American journal of cardiology. 2010. Shiffman Dov, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of membrane transporters: past, present and future. Pharmacogenomics. 2010. Yee Sook Wah, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenetics and genomics. 2010. Oshiro Connie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins. Pharmacogenomics. 2010. Chien Kuo-Liong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Transporter pharmacogenetics and statin toxicity. Clinical pharmacology and therapeutics. 2010. Niemi M. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genome-wide association of lipid-lowering response to statins in combined study populations. PloS one. 2010. Barber Mathew J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms. Journal of clinical pharmacology. 2009. Ide Takafumi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The pharmacogenetics of statin therapy: when the body aches, the mind will follow. Journal of the American College of Cardiology. 2009. Rossi Joseph S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Identification of genetic variants associated with response to statin therapy. Arteriosclerosis, thrombosis, and vascular biology. 2009. Mega Jessica L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics. 2009. Willrich Maria Alice Vieira, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional analysis of a mutation in the SLCO1B1 gene (c.1628T>G) identified in a Japanese patient with pravastatin-induced myopathy. The pharmacogenomics journal. 2009. Furihata Tomomi, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of R219K polymorphism of the ABCA1 gene on the lipid-lowering effect of pravastatin in Chinese patients with coronary heart disease. Clinical and experimental pharmacology & physiology. 2009. Li Jia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The SLCO1B1*5 genetic variant is associated with statin-induced side effects. Journal of the American College of Cardiology. 2009. Voora Deepak, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study. Pharmacogenetics and genomics. 2009. Maitland-van der Zee Anke-Hilse, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics. 2009. Keskitalo Jenni E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics. 2009. Franke Ryan M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenetics and genomics. 2008. Donnelly Louise A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. European heart journal. 2008. Regieli Jakub J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis. 2008. Polisecki Eliana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. Pharmacogenetics and genomics. 2008. Maitland-van der Zee Anke-Hilse, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Machine learning methods and docking for predicting human pregnane X receptor activation. Chemical research in toxicology. 2008. Khandelwal Akash, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nature medicine. 2008. Varela Ignacio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Hagenbuch B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. American journal of human genetics. 2008. Reiner Alexander P, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation. 2008. Krauss Ronald M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circulation. Cardiovascular genetics. 2008. Voora Deepak, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate. Pharmacogenetics and genomics. 2008. Pasanen Marja K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Statins inhibit toll-like receptor 4-mediated lipopolysaccharide signaling and cytokine expression. Pharmacogenetics and genomics. 2008. Hodgkinson Conrad P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenetics and genomics. 2008. Deng Jian Wei, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arteriosclerosis, thrombosis, and vascular biology. 2008. Sabatine Marc S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. Expert opinion on drug metabolism & toxicology. 2008. Seithel Annick, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. Journal of the American College of Cardiology. 2008. Iakoubova Olga A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. Journal of the American College of Cardiology. 2008. Iakoubova Olga A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. Journal of human genetics. 2008. Suwannakul Suttasinee, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Long-term follow-up of the West of Scotland Coronary Prevention Study. The New England journal of medicine. 2007. Ford Ian, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. British journal of clinical pharmacology. 2007. Zhang Wei, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients. Journal of lipid research. 2007. Singer Jonathan B, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of statin response. Current opinion in lipidology. 2007. Mangravite Lara M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenetics and genomics. 2007. Ho Richard H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. Journal of atherosclerosis and thrombosis. 2007. Davis Harry R, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle & nerve. 2007. Ruaño Gualberto, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacological research : the official journal of the Italian Pharmacological Society. 2007. Zuccaro Piergiorgio, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. The Journal of pharmacology and experimental therapeutics. 2007. Faucette Stephanie R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Asp92Asn polymorphism in the myeloid IgA Fc receptor is associated with myocardial infarction in two disparate populations: CARE and WOSCOPS. Arteriosclerosis, thrombosis, and vascular biology. 2006. Iakoubova Olga A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenetics and genomics. 2006. Niemi Mikko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clinical pharmacology and therapeutics. 2006. Niemi Mikko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle & nerve. 2006. Vladutiu Georgirene D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. British journal of clinical pharmacology. 2006. Hedman Mia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clinical pharmacology and therapeutics. 2006. Neuvonen Pertti J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clinical pharmacology and therapeutics. 2006. Igel Michael, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment. Atherosclerosis. 2005. Lahoz Carlos, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia. European journal of human genetics : EJHG. 2005. Mohrschladt Martina F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenetics and genomics. 2005. Niemi Mikko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenetics and genomics. 2005. Kameyama Yoshio, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
An association study of 43 SNPs in 16 candidate genes with atorvastatin response. The pharmacogenomics journal. 2005. Thompson J F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics. 2004. Niemi Mikko, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA : the journal of the American Medical Association. 2004. Chasman Daniel I, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease. Circulation. 2004. Ledmyr Helena, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clinical pharmacology and therapeutics. 2004. Mwinyi Jessica, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Human molecular genetics. 2004. Knoblauch Hans, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics. 2004. Kivistö Kari T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. American heart journal. 2003. Carlquist John F, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Interleukin-1B genotype modulates the improvement of coronary artery reactivity by lipid-lowering therapy with pravastatin: a placebo-controlled positron emission tomography study in young healthy men. Pharmacogenetics. 2003. Lehtimäki Terho, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clinical pharmacology and therapeutics. 2003. Nishizato Yohei, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation. 2003. Boekholdt S Matthijs, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
DD ACE gene polymorphism is associated with increased coronary artery endothelial dysfunction: the PREFACE trial. Heart (British Cardiac Society). 2003. Mulder H J G H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of the factor XII 46C>T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study. Atherosclerosis. 2002. Zito Francesco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A cell-based reporter gene assay for determining induction of CYP3A4 in a high-volume system. The Journal of pharmacology and experimental therapeutics. 2002. Raucy Judy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS). Arteriosclerosis, thrombosis, and vascular biology. 2002. Basso Federica, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. The American journal of cardiology. 2001. Bray P F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Increased risk for ischaemic events is related to combined RAS polymorphism. Heart (British Cardiac Society). 2001. van Geel P P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharmaceutics & drug disposition. 2000. Cohen L H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and P13 kinase. Journal of the American Society of Nephrology : JASN. 1999. Weiss R H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pravastatin, an HMG-CoA reductase inhibitor, is transported by rat organic anion transporting polypeptide, oatp2. Pharmaceutical research. 1999. Tokui T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. The Journal of biological chemistry. 1999. Hsiang B, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. The American journal of cardiology. 1999. de Maat M P, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
-455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group. Arteriosclerosis, thrombosis, and vascular biology. 1998. de Maat M P, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. The New England journal of medicine. 1998. Kuivenhoven J A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis. 1995. Ordovas J M, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0003-5154-05
DrugBank:
DB00175
KEGG Compound:
C01844
PubChem Compound:
54687
PubChem Substance:
192211
46504851
Drugs Product Database (DPD):
2247008
BindingDB:
20688
ChemSpider:
49398
Therapeutic Targets Database:
DAP000550
FDA Drug Label at DailyMed:
897ad8b7-921d-eb02-a61c-3419e662a2da

Clinical Trials

These are trials that mention pravastatin and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.